TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Humacyte ( (HUMA) ) has provided an update.
Humacyte, Inc. announced the termination of its Open Market Sale Agreement with Jefferies LLC, effective November 21, 2025. The termination of this agreement, which allowed the sale of common stock up to $80 million, will not incur any penalties for the company.
The most recent analyst rating on (HUMA) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.
Spark’s Take on HUMA Stock
According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.
Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise.
To see Spark’s full report on HUMA stock, click here.
More about Humacyte
Humacyte, Inc. operates in the biotechnology industry, focusing on developing bioengineered human tissue for use in regenerative medicine and other medical applications.
Average Trading Volume: 5,170,116
Technical Sentiment Signal: Sell
Current Market Cap: $247.2M
See more data about HUMA stock on TipRanks’ Stock Analysis page.